Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Next Previous
Trial Profile

Phase I/II study of Pelareorep in combination with atezolizumab with or without chemotherapy in patients with advanced or metastatic GI tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Tipiracil/trifluridine
  • Indications Adenocarcinoma; Anal cancer; Colorectal cancer; Gastrointestinal cancer; Pancreatic ductal carcinoma; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GOBLET

Most Recent Events

  • 28 Oct 2025 According to an Oncolytics Biotech media release, based on the compelling data, company intends to engage the U.S. Food and Drug Administration (FDA) to discuss a potential single-arm study designed for accelerated approval in second-line or later SCAC, with a potential launch date for such a study expected in the first half of 2026/Q1 2026.
  • 28 Oct 2025 Results presented in an Oncolytics Biotech media release
  • 28 Oct 2025 According to an Oncolytics Biotech media release, updated results from the single-arm squamous cell anal carcinoma (SCAC) cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab and patients in this cohort continue to be followed, and additional efficacy data are expected.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top